
Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

This case highlights the importance of recognizing ICPI-AKI, implementing effective therapeutic interventions, and understanding the clinical context to prevent irreversible renal damage.

Migraine is a chronic neurological disease characterized by throbbing or pulsating unilateral or bilateral headache that can last from hours to days.








January 1st 2006

November 1st 2006

January 1st 2006

December 1st 2005